Medicenna Therapeutics Corporation (MDNA) News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Medicenna Announces Results of Annual and Special Meeting of Shareholders

TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Medicenna to Participate at The H.C. Wainwright 25th Annual Global Investment Conference

TORONTO and HOUSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management

Company to grow business development, financing and clinical leadership in Boston by accessing top-biotech...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee 

TORONTO and HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]